非霍奇金淋巴瘤患者利妥昔单抗化疗后肺部并发症的特点及对生存率的影响

目的:探讨非霍奇金淋巴瘤（non-Hodgkin' s lymphoma，NHL）患者接受利妥昔单抗化疗后肺部并发症的发生率、发病特点及对生存率的影响。方法:收集2011年1月至2016年6月在我院接受含利妥昔单抗方案化疗的163例NHL患者作为研究对象，观察患者肺部并发症的发生率、发病特点，采用单因素与多因素分析观察肺部并发症与患者3年死亡率的相关性。结果:163例患者中共37例患者发生64例次呼吸系统并发症，并发症发生率为22.70％。肺部并发症和无肺部并发症患者性别、年龄、体质量指数、NHL类型、NHL分期、左心室射血分数、利妥昔单抗总剂量相比较差异均无统计学意义（P＞0.05），肺部并发症患者肺/胸膜受累患者百分率高于无肺部并发症患者，差异有统计学意义（P＜0.05）。患者3年生存率为80.98％。单因素和多因素分析均显示，肺部并发症是影响NHL患者预后的风险因素（P＜0.05）。结论:NHL接受利妥昔单抗化疗后肺部并发症与患者3年死亡风险增加相关。

Characteristics of pulmonary complications in patients with non-Hodgkin' s lymphoma after rituximab chemotherapy and its impact on survival rate

Objective:To investigate the incidence and characteristics of pulmonary complications in patients with non-Hodgkin' s lymphoma (NHL) after rituximab chemotherapy and its impact on survival rate.Methods:163 NHL patients who received rituximab chemotherapy in our hospital from January 2011 to June 2016 were selected,and the incidence and characteristics of pulmonary complications were observed.The correlation between pulmonary complications and 3-year mortality was observed by single and multiple factor.Results:In 163 patients,37 patients had 64 respiratory complications.The incidence of complications was 22.70%.There were no significant differences in gender,age,body mass index,NHL type,NHL stage,left ventricular ejection fraction and total dose of rituximab between patients with and without pulmonary complications (P＞0.05).The percentage of pulmonary/pleural involvement in patients with pulmonary complications was higher than that in patients without pulmonary complications (P＜0.05).The 3-year survival rate of NHL patients was 80.98%.The single and multiple factors showed pulmonary complications were the risk factors affecting the prognosis of NHL patients (P＜0.05).Conclusion:The pulmonary complications following rituximab chemotherapy in NHL patients are associated with an increased risk of 3-year mortality.